Fulcrum Therapeutics focuses on rare genetic diseases with losmapimod in Phase 3 trial; stock is down 56% since February. Fulcrum's financial health is strong with $278.2M in cash; monthly cash burn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results